Evogene Ltd. (EVGN) announced on February 4 2026 that its subsidiary Biomica has entered into an exclusive worldwide licensing agreement with Shanghai Lishan Biopharmaceuticals Co., Ltd. (Lishan Biotech) for the microbiome‑based therapeutic BMC128, a first‑in‑class candidate designed to enhance anti‑tumor immune activity in renal and lung cancer patients.
The deal gives Lishan Biotech exclusive rights to develop, manufacture, and commercialize BMC128 globally, while Biomica retains ownership of the underlying technology and will receive milestone payments and a share of future sales. The partnership positions Evogene to tap into the rapidly growing oncology microbiome market, potentially generating significant milestone revenue and establishing a foothold in a high‑margin therapeutic area.
By securing this license, Evogene expands its portfolio beyond agricultural and small‑molecule drug discovery into a clinically validated oncology platform, diversifying its revenue streams and strengthening its strategic shift toward pharmaceutical applications. The agreement also signals confidence from a China‑based biopharma partner in Evogene’s technology, which could accelerate future collaborations and broaden the company’s global reach.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.